Pleurodesis For Spontaneous Pneumothorax
Will the Procedure of Choice Please Stand Up? 1n this issue of Chest (see page 1162), Milanez and colleagues describe their experience with thoracoscopic management of spontaneous pneumothorax. They report that after the intrapleural insulflation of 2 g of sterile asbestos-free talc, only 1 of 18 patients had a recurrence over a period of follow-up ranging from 1 to over 3 years. This is an important observation because the problems presented by recurrent spontaneous pneumothorax are not trivial ones. The estimated incidence in the US alone is about 17,000 cases per year,1 and the recurrence rate is 23 to 50% after the first episode, and higher after the first recurrence.2-4 Thus, the morbidity and even mortality related to this problem are quite considerable, and the potential direct and indirect costs resulting from spontaneous pneumothorax can add up to tens of millions of dollars each year. The search for a rapid, safe, inexpensive, and highly effective way to prevent recurrence has been going on for decades. In general, all proposed approaches have fallen into one of three types: surgical interventions via a standard thoracotomy, intrapleural instillation (through a conventional chest-tube thoracostomy) of a sclerosing chemical agent, and more recently, thoracoscopic surgery and pleurodesis. Unfortunately, few prospective, controlled studies of any of these forms of therapy have ever been published, and even fewer have directly compared two or more different methods.
The surgical approach to achieve obliteration of the pleural space has traditionally been the gold standard in terms of efficacy, but the inherent risk and expense associated with a thoracotomy have made this a less than ideal first choice. The intrapleural instillation of a suitable chemical agent is easy and far safer than surgery. For these reasons, and because of its low cost (about $48 for 2 g in 1989), the use of tetracycline in this manner, though largely empirical, rapidly became widespread. The publication of the Veterans Administration Cooperative Study2 and other series5-7 eventually confirmed its excellent efficacy and safety in this setting, and intrapleural instillation of tetracycline was widely accepted as the treatment of choice. Its success, however, was short-lived. Since about 1991, the US production and marketing of parenteral intravenous tetracycline hydrochloride was discontinued by the manufacturer because the market source of the sterile tetracycline salt needed for production was no longer available. On the other hand, published evidence does suggest that insufflating sterile asbestos-free talc may be one of the best methods of achieving pleurodesis through the use of a chemical irritant. In this regard, the 95% success rate reported by Milanez and colleagues in the present issue of Chest compares favorably with the 88% success rate described by van de Brekel and coworkers22 in 356 patients with spontaneous pneumothorax treated in similar fashion. If talc is to be used, thoracoscopy does offer the advantage of allowing its direct insufflation in powder form, and thus, the somewhat cumbersome task of preparing a sterile "slurry" is avoided. However, although talc is very inexpensive (less than $1.00 for 10 g, nonsterile), its availability in sterile form may be limited in certain hospitals, and possible (though rare and/or not yet fully proved) severe toxicity has been reported with its use.23-25 Furthermore, initial studies with doxycycline and minocycline, albeit including few patients, have also shown success rates in the 75 to 90% range (Table 1) . Thus, since these drugs also are easier to use, reasonably safe, and readily available everywhere, talc probably cannot yet be proposed as the unquestionable preferred agent for chemical pleurodesis. Table 1 summarizes some of the published data regarding the efficacy of different methods of pleurodesis. When available, data have been included on both spontaneous pneumothorax and malignant effusions. Excluded are published data on the use of nitrogen mustard, methylprednisolone, mitomycin-C, doxorubicin, etoposide, fluorouracil, interferon-f, cisplatin, and others, because these agents have been used mostly or exclusively for malignant effusions, the total number of patients treated with each of them is very small, and their efficacy (at least in this clinical scenario) has been low, ranging from 0% for etoposide to about 40% for interferon-d and mitomycin C.
In conclusion, I believe that the current study and other published data22 clearly support the use of thoracoscopy for the prevention of recurrence of spontaneous pneumothorax. Although issues of safety and cost prevent this approach from being the ideal routine, thoracoscopy probably is the best available option for those patients in whom a previous attempt at chemical pleurodesis through a conventional chesttube thoracostomy has failed, and/or for those in whom any recurrence of pneumothorax is judged likely to be life threatening. As Milanez and coworkers point out, however, whether it is best to attempt thoracoscopic pleurodesis by pleurectomy, by mechanical or thermal abrasion, by insufflation of asbestos-free talc, or even by the use of intrapleural tetracycline, minocycline, or doxycycline, it remains an unresolved issue. Until properly controlled clinical trials are funded and carried out, the choice of sclerosing agent will remain largely a matter of
